Anti-Coagulants - North Macedonia

North Macedonia

In North Macedonia, the revenue in the Anti-Coagulants market is forecasted to reach US$2.44m in 2024.
It is expected that the revenue will exhibit an annual growth rate (CAGR 2024-2029) of 8.21%, leading to a market volume of US$3.62m by 2029.
When compared globally, United States is projected to generate the highest revenue in the Anti-Coagulants market, amounting to US$16,740.00m in 2024.
The demand for anti-coagulants in North Macedonia is steadily increasing due to the aging population and rising prevalence of cardiovascular diseases.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Coagulants market in North Macedonia has been experiencing steady growth in recent years.

Customer preferences: Patients in North Macedonia are increasingly seeking out Anti-Coagulant medications due to the rise in cardiovascular diseases and the aging population. Additionally, there is a growing awareness among patients and healthcare professionals regarding the benefits of Anti-Coagulants in preventing blood clots and reducing the risk of stroke.

Trends in the market: The Anti-Coagulants market in North Macedonia is dominated by oral Anti-Coagulants, with newer drugs such as Factor Xa inhibitors gaining popularity due to their ease of use and lower risk of bleeding compared to traditional Warfarin. The market is also seeing an increase in the use of combination therapy, where patients are prescribed more than one Anti-Coagulant medication to achieve better outcomes.

Local special circumstances: One of the unique factors in the North Macedonian market is the government's efforts to make healthcare more accessible to its citizens. The government has implemented policies to increase the availability of healthcare services, including the provision of free Anti-Coagulant medications to patients who cannot afford them. This has contributed to the growth of the Anti-Coagulants market in the country.

Underlying macroeconomic factors: The growth of the Anti-Coagulants market in North Macedonia is also influenced by macroeconomic factors such as the country's GDP growth and healthcare spending. As the country's economy continues to improve, more funds are being allocated to healthcare, which is driving the growth of the Anti-Coagulants market. Additionally, the government's efforts to integrate North Macedonia into the European Union have led to the adoption of EU healthcare standards, which has also contributed to the growth of the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.